Navigation Links
Gregory J. Tibbitts Appointed Chief Financial Officer at Accumetrics, Inc.
Date:2/26/2009

SAN DIEGO, Calif., Feb. 26 /PRNewswire/ -- Accumetrics, Inc. announced today that the Company has appointed Gregory J. Tibbitts, CPA to the position of Chief Financial Officer.

"We believe Greg's extensive experience in both private and public companies will help Accumetrics to advance our financial operations and bring continued success to the Company," says Timothy I. Still, Chief Executive Officer at Accumetrics. "His deep knowledge of the capital markets and the medical device arena will be important as we maximize the commercial opportunity for our technology."

Mr. Tibbitts's background includes 19 years of corporate finance and technical accounting experience balanced between public accounting and private industry. He has held positions with both publicly traded and privately-held companies, with expertise in risk management, treasury, financing and financial operations.

Prior to Accumetrics, Mr. Tibbitts served as Chief Financial Officer of CryoCor, a publicly-traded medical device company, prior to its acquisition by Boston Scientific Corporation. Mr. Tibbitts joined CryoCor in mid-2004, and was heavily involved in both its Initial Public Offering in July 2005 and its ultimate acquisition in 2008 by Boston Scientific. Before joining CryoCor, Mr. Tibbitts served as Chief Financial Officer of Elitra Pharmaceuticals, a privately-held biotechnology company, and as a Senior Manager in the audit practice of Ernst & Young LLP.

Mr. Tibbitts received a BBA degree from the University of San Diego, and an MBA from San Diego State University, and serves on the Board of Directors of IDMI Pharmaceuticals, a publicly-traded biotechnology company.

About Accumetrics (www.accumetrics.com)

Accumetrics is committed to advancing medical understanding of platelet response and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.

Accumetrics' VerifyNow System is the first rapid and easy to use platform for measuring an individual's response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, Plavix(R), ReoPro(R), and Integrilin(R), the VerifyNow System provides a valuable tool to help physicians make informed treatment decisions.

The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc. ReoPro is a registered trademark of Centocor, Inc. Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is a registered trademark of Sanofi-Aventis.

    CONTACT:    Jules Abraham
                Lippert Heilshorn & Associates
                212-838-3777
                jabraham@lhai.com

                Timothy I. Still
                Accumetrics
                press@accumetrics.com


'/>"/>
SOURCE Accumetrics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Dr. Gregory Sawyer, of Los Gatos, Has Been Selected by the American Dental Association for the Evidence-Based Dentistry Champion Conference
2. MDdatacor Names Gregory Buchholz Chief Operating Officer
3. American Hospital Management Company Appoints Gregory Ciottone, MD as Chief Medical Officer
4. Congressman Gregory W. Meeks to Ask for Suspension of CARES Process at the St. Albans Veteran Campus
5. Synthetech Announces Appointment of Dr. Gregory R. Hahn as President and Chief Executive Officer
6. Gregory A. Adams Named Northern California Region President of Kaiser Foundation Health Plan and Hospitals
7. Dr. Gregory Buford and Top Plastic Surgeon Selected as a Keynote Speaker at Spa & Resort Expo LA Convention Center, February 23-25
8. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
9. Brickson Diamond Appointed Board Chair of National Hospice Foundation
10. Valensa Internationals Dr. Rudi E. Moerck Appointed CEO
11. Margaret Laub Appointed to IntelliDOT Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... Levels of a protein in the blood ... study appearing online in the journal Radiology. , Heart disease and brain disease exact ... to the rapidly aging population. Damage to both organs often occurs at a subclinical ...
(Date:12/7/2016)... ... December 07, 2016 , ... ODU, ... to the US market its advanced highly customizable contact technology solutions. , ODU ... These advanced technologies are ideal for a wide range of applications that require ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... planning services to families and business owners in the greater Dallas metropolitan area, ... the Dallas Fallen Officer Foundation. , Established in 2009 by active police professionals ...
(Date:12/7/2016)... ... 2016 , ... A. Kevin Spann Insurance, a New York-based firm offering insurance ... launching a charity drive to raise funds that will benefit the Marine Corps League. ... and Navy FMF Corpsmen. Working closely with the MCL, the A. Kevin Spann team ...
(Date:12/7/2016)... Honolulu, HI (PRWEB) , ... December 07, 2016 ... ... Dermatology is proud to announce that its fully redesigned website, which launched October ... well as a sleek responsive design and easy-to-navigate layout. Visitors and patients can ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... Biosimilar Clinical Trial & Opportunity Insight" report by PNS Pharma gives comprehensive ... Currently 5 biosimilar version of Lantus are commercially available in ... , Czech Republic , Estonia , ... Slovakia , United Kingdom for the treatment ... in 2014. Lantus is the brand name for Insulin Glargine, a ...
(Date:12/7/2016)... Global Cervical Dysplasia Market: Scope and ... dysplasia market analyzes the current and future prospects ... executive summary, including a market snapshot that provides ... The research is a combination of primary and ... our research efforts along with information collected from ...
(Date:12/7/2016)... -- A new investigational drug originally developed for type 2 ... of the world,s first treatment to impede the progression of ... in the journal Science Translational Medicine . ... for millions of people living with Parkinson,s disease," says ... Research Institute,s Center for Neurodegenerative Science , chairman ...
Breaking Medicine Technology: